Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 11c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $4.11 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Appeals court allows Trump administration to expand fast-track deportation process
• BofA lists top 5 themes driving next $1tn in incremental semi sales